New analysis of trial of semaglutide in adolescents shows it can reduce liver enzymes indicative of liver damage

A new sub-study of the STEP TEENS trial, presented at this year’s European Congress on Obesity (ECO) 2023 in Dublin May 17-20, shows that adolescents using semaglutide experienced significant reductions in levels of liver enzymes that are an indicator of liver damage. The study is by Dr. Daniel Weghuber, Department of Pediatrics, Paracelsus Medical University, Salzburg, Austria, and Dr. Rasmus Sørrig, Novo Nordisk A/S (the manufacturer of semaglutide), Søborg, Denmark, and colleagues.